Axsome Therapeutics Inc (AXSM) Expected to Announce Earnings of -$0.32 Per Share

Share on StockTwits

Equities research analysts expect Axsome Therapeutics Inc (NASDAQ:AXSM) to post ($0.32) earnings per share for the current quarter, Zacks reports. Zero analysts have made estimates for Axsome Therapeutics’ earnings. Axsome Therapeutics posted earnings per share of ($0.30) in the same quarter last year, which would indicate a negative year over year growth rate of 6.7%. The business is scheduled to issue its next quarterly earnings report on Wednesday, August 8th.

On average, analysts expect that Axsome Therapeutics will report full year earnings of ($1.08) per share for the current year, with EPS estimates ranging from ($1.11) to ($1.04). For the next financial year, analysts forecast that the company will post earnings of ($0.68) per share, with EPS estimates ranging from ($1.11) to ($0.24). Zacks’ EPS calculations are a mean average based on a survey of analysts that that provide coverage for Axsome Therapeutics.

Axsome Therapeutics (NASDAQ:AXSM) last announced its quarterly earnings results on Tuesday, May 8th. The company reported ($0.19) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.28) by $0.09.

A number of brokerages have recently issued reports on AXSM. Zacks Investment Research raised shares of Axsome Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, May 8th. ValuEngine raised shares of Axsome Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, May 2nd. HC Wainwright began coverage on shares of Axsome Therapeutics in a report on Thursday, June 7th. They issued a “buy” rating and a $10.00 price target on the stock. Finally, BTIG Research reissued a “buy” rating and issued a $16.00 price target on shares of Axsome Therapeutics in a report on Sunday, April 29th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and five have assigned a buy rating to the company’s stock. Axsome Therapeutics presently has a consensus rating of “Buy” and an average target price of $16.08.

Shares of Axsome Therapeutics traded down $0.25, reaching $3.00, on Tuesday, MarketBeat reports. The stock had a trading volume of 914,202 shares, compared to its average volume of 142,988. Axsome Therapeutics has a 1 year low of $2.05 and a 1 year high of $6.45. The company has a market cap of $82.84 million, a price-to-earnings ratio of -2.42 and a beta of -0.31. The company has a current ratio of 2.95, a quick ratio of 2.95 and a debt-to-equity ratio of 0.47.

Hedge funds have recently bought and sold shares of the stock. Goldman Sachs Group Inc. bought a new position in shares of Axsome Therapeutics in the fourth quarter worth approximately $238,000. Renaissance Technologies LLC bought a new position in shares of Axsome Therapeutics in the fourth quarter worth approximately $271,000. A.R.T. Advisors LLC bought a new position in shares of Axsome Therapeutics in the first quarter worth approximately $145,000. Sabby Management LLC bought a new position in shares of Axsome Therapeutics in the first quarter worth approximately $199,000. Finally, Sio Capital Management LLC bought a new position in shares of Axsome Therapeutics in the first quarter worth approximately $474,000. Institutional investors own 16.49% of the company’s stock.

About Axsome Therapeutics

Axsome Therapeutics, Inc, a clinical stage biopharmaceutical company, is developing novel therapies for central nervous system (CNS) disorders. Its product candidate portfolio includes AXS-05, AXS-09, AXS-02, AXS-07, and AXS-06. AXS-05 is in the Phase III clinical trial in treatment resistant depression and in agitation associated with Alzheimer's disease, as well as in the Phase II clinical trial for smoking cessation.

Get a free copy of the Zacks research report on Axsome Therapeutics (AXSM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Axsome Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axsome Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Infosys Ltd  Shares Sold by Bank of Montreal Can
Infosys Ltd Shares Sold by Bank of Montreal Can
Bank of Montreal Can Sells 274,772 Shares of Vertex Pharmaceuticals Incorporated
Bank of Montreal Can Sells 274,772 Shares of Vertex Pharmaceuticals Incorporated
Fox Run Management L.L.C. Purchases 8,011 Shares of Patterson Companies, Inc.
Fox Run Management L.L.C. Purchases 8,011 Shares of Patterson Companies, Inc.
Contrasting General Motors  & Spartan Motors
Contrasting General Motors & Spartan Motors
Fox Run Management L.L.C. Takes Position in Prologis Inc
Fox Run Management L.L.C. Takes Position in Prologis Inc
23,332 Shares in First Data Corp  Purchased by Fox Run Management L.L.C.
23,332 Shares in First Data Corp Purchased by Fox Run Management L.L.C.


© 2006-2018 Ticker Report. Google+.